SGLT2 Inhibitors Market to Witness Significant Growth by 2034 Driven by Expanding Indications Beyond Type 2 Diabetes | DelveInsight

DelveInsight's "Sodium-glucose co-transporter-2 (SGLT2) inhibitors Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the SGLT2 inhibitors, historical and Competitive Landscape as well as the SGLT2 inhibitor market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the SGLT2 Inhibitors Market Report @ https://www.delveinsight.com/report-store/sglt2-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from SGLT2 Inhibitors Market Report
• In July 2026, Colorado Prevention Center announced result of Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF).
• In the United States, recent milestones include FDA approval of BRENZAVVY (bexagliflozin) for glycemic control in 2023 and expansion of JARDIANCE into CKD.
• INPEFA, a dual SGLT1/2 inhibitor, was approved in 2023 for heart failure, with new 2025 data showing a 23% reduction in heart attacks, strokes, and cardiovascular deaths.
• In Japan, dapagliflozin gained approvals for CKD with or without diabetes, and in 2025, Mitsubishi Tanabe launched CANALIA, the first once-daily oral combination of a DPP-4 inhibitor and an SGLT2 inhibitor.
• In the UK, SGLT2 inhibitors are being considered as first-line therapy in NHS guidelines, with dapagliflozin and empagliflozin already widely used for diabetes, heart failure, and CKD.
• With obesity affecting over 650 million adults globally and type 2 diabetes impacting more than 400 million individuals, SGLT2 inhibitors have the potential to improve the lives of millions.
• As per DelveInsight's consultant, there were 191 million prevalent cases of obesity (adults and children) in the US in 2024, while over 32 million incident cases were of type 2 diabetes in the US in the same year.
• In the 7MM, the largest eligible population for promising SGLT2 inhibitor indications in 2024 was observed in the United States, followed by the EU4 countries and the United Kingdom, with Type 2 diabetes mellitus being the leading condition.
• As per DelveInsight, the total diagnosed prevalent cases of CKD in the US were ~3,770,000 in 2024, and total diagnosed prevalent cases of CHF in the US were ~7,200,000 in 2024.
• As per the American Diabetes Association, in the US, there are approximately 38 million cases of diabetes, with about 90-95% of them being type 2 diabetes.
• The SGLT2 Inhibitors Companies include Janssen (J&J), AstraZeneca, Boehringer Ingelheim/Eli Lilly, TheracosBio, Mitsubishi Tanabe Pharma, and others.
• Promising SGLT2 Inhibitors in clinical trials include YG1699 (Youngene Therapeutics), JP-2266 (Jeil Pharmaceuticals), and others.

Get a Free sample for the SGLT2 Inhibitors Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/sglt2-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What are SGLT2 Inhibitors?
SGLT2 inhibitors are oral prescription medicines widely used to manage type 2 diabetes and protect kidney and cardiovascular health. By blocking SGLT2 proteins in the renal proximal tubules, they reduce glucose reabsorption and increase urinary glucose excretion. Drugs such as INVOKANA, FARXIGA/FORXIGA, JARDIANCE, and BRENZAVVY can improve glycemic control, lower uACR, slow chronic kidney disease progression, and reduce heart failure and cardiovascular risks. Growing research is also exploring their potential applications in broader therapeutic areas, including solid tumors.

SGLT2 Inhibitors Epidemiology Segmentation in the 7MM
• Total Cases in Selected Indications for SGLT2 Inhibitors
• Total Eligible Patient Pool in Selected Indications for SGLT2 Inhibitors
• Total Treated Cases in Selected Indications for SGLT2 Inhibitors

Download the report to understand which factors are driving SGLT2 Inhibitors epidemiology trends @ https://www.delveinsight.com/report-store/sglt2-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

SGLT2 Inhibitors Marketed Therapies
• BRENZAVVY (bexagliflozin): TheracosBio
BRENZAVVY, an oral SGLT2 inhibitor, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not recommended for individuals with type 1 diabetes mellitus. The FDA approval was supported by a clinical development program comprising 23 trials involving more than 5,000 adults with type 2 diabetes mellitus. Phase III studies demonstrated that BRENZAVVY significantly lowered hemoglobin A1c and fasting blood glucose levels after 24 weeks, whether used as monotherapy, alongside metformin, or as an add-on to standard treatments such as metformin, sulfonylureas, insulin, DPP4 inhibitors, or combinations of these therapies.

• JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly
JARDIANCE is an oral SGLT2 inhibitor developed by Boehringer Ingelheim and Eli Lilly, first approved by the US FDA in August 2014 for the treatment of type 2 diabetes. It works by blocking the sodium-glucose co-transporter 2 in the kidneys, which reduces glucose and sodium reabsorption, leading to increased glucose excretion through urine and improved blood sugar control. Beyond its role in diabetes, JARDIANCE has shown significant benefits in cardiovascular and kidney health, and in June 2023, the FDA approved JARDIANCE for the treatment of type 2 diabetes in children 10 years and older.

SGLT2 Inhibitors Pipeline Analysis
• YG1699: Youngene Therapeutics
YG1699 is a dual systemic inhibitor of SGLT1 and SGLT2. It blocks SGLT2 activity in the early proximal tubule and SGLT1 activity in the late proximal tubule of the nephron, and in the small intestine, it reduces SGLT1-mediated glucose absorption while stimulating GLP-1 and PYY secretion. These combined effects may provide advantages over selective SGLT2 inhibitors, including improved glycemic control, enhanced glomerular filtration, and better kidney oxygenation, ultimately helping to delay the progression of kidney and heart failure by preserving renal function. The therapy is currently in Phase II clinical trials for type 2 diabetes mellitus (T2DM) and in Phase I trials for cystic fibrosis, diabetes with severe chronic kidney disease (CKD), type 1 diabetes, and heart failure.

• JP-2266: Jeil Pharmaceuticals
JP-2266 is a small-molecule dual inhibitor of SGLT1/2 currently in Phase II development, being investigated for the treatment of type 2 diabetes to improve glycemic control, as well as type 1 diabetes in patients who fail to achieve adequate control despite optimal insulin therapy. The drug acts by inhibiting renal SGLT2, promoting significant urinary glucose excretion similar to existing SGLT2 inhibitors, while also blocking intestinal SGLT1 to delay glucose absorption and reduce postprandial glucose levels.

SGLT2 Inhibitors Companies
Janssen (J&J), AstraZeneca, Boehringer Ingelheim/Eli Lilly, TheracosBio, Mitsubishi Tanabe Pharma, Youngene Therapeutics, Jeil Pharmaceuticals, and others

Discover more about therapies set to grab major SGLT2 Inhibitors market share @ https://www.delveinsight.com/sample-request/sglt2-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

SGLT2 Inhibitors Market Outlook
SGLT2 inhibitors, originally developed to manage type 2 diabetes, have evolved into key therapies for CKD and heart failure, demonstrating strong cardiovascular and renal benefits beyond glucose control. Agents like empagliflozin, dapagliflozin, and canagliflozin have maintained widespread use due to their favorable safety profiles. The SGLT2 Inhibitors Market landscape is expanding, with ongoing research exploring their use in conditions such as obesity, NASH, and PCOS. Additionally, combination approaches pairing SGLT2 inhibitors with GLP-1 receptor agonists or mineralocorticoid receptor antagonists are gaining traction, aiming to enhance efficacy and minimize side effects. The future of SGLT2 inhibitors lies in innovative, multi-targeted strategies that address complex chronic diseases beyond diabetes.

Scope of the SGLT2 Inhibitors Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM (US, EU4 [Germany, France, Italy, and Spain], the UK, and Japan)
• SGLT2 Inhibitors Companies: Janssen (J&J), AstraZeneca, Boehringer Ingelheim/Eli Lilly, TheracosBio, Mitsubishi Tanabe Pharma, and others
• SGLT2 Inhibitors Therapies: INVOKANA, FARXIGA/FORXIGA, JARDIANCE, BRENZAVVY, and others
• SGLT2 Inhibitors Epidemiology Segmentation: Total Cases in Selected Indications, Total Eligible Patient Pool in Selected Indications, Total Treated Cases in Selected Indications
• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis
• SGLT2 Inhibitors Market Access and Reimbursement, Unmet Needs, and KOL's Views

To know more about SGLT2 Inhibitors companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/sglt2-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of SGLT2 Inhibitors
4. Key Events
5. SGLT2 Inhibitors Market Overview At A Glance
6. Background And Overview
7. SGLT2 Inhibitors Target Population
8. SGLT2 Inhibitors Marketed Drugs
9. SGLT2 Inhibitors Emerging Drugs
10. SGLT2 Inhibitors: The 7MM Analysis
11. SGLT2 Inhibitors Unmet Needs
12. SWOT Analysis
13. KOL Views
14. Market Access and Reimbursement
15. Appendix
16. Delveinsight Capabilities
17. Disclaimer
18. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.